The layoffs will allow Ironwood to dedicate more resources to pushing its lead molecule apraglutide through a Phase III trial ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Kennedy’s confirmation hearing on Wednesday became heated as Democratic senators grilled the nominee for HHS Secretary on his ...

The move is part of a strategic restructuring aimed at getting azenosertib to the market for patients with gynecological ...

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

Ahead of Robert F. Kennedy Jr.’s confirmation hearings, experts—and RFK’s own family—expressed concerns about his ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after ...